Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza
Status:
Completed
Trial end date:
2019-08-30
Target enrollment:
Participant gender:
Summary
Assessment of the effect reached with the different doses of AV5080 on the duration and
severity of influenza symptoms based on the incidence of their resolution within 96 hours
from study treatment initiation compared to Placebo.
The absence of influenza symptoms or their reduction to mild severity for at least 24 hours
indicates the resolution of influenza.